Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Global atrial fibrillation market is expected to grow to $12.5 billion by 2020

  • Home Blog Global atrial fibrillation market is expected to grow to 12 5 billion by 2020 with and compound annual growth rate cagr of 11 62

Global atrial fibrillation market is expected to grow to $12.5 billion by 2020

May 12, 2016

Global AF market was $7.2 billion in 2015 and expected to grow to $12.5 billion by 2020 with and compound annual growth rate (CAGR) of 11.62%. There are four NOACs which are indicated for the treatment of AF such as Xarelto, Eliquis, Pradaxa and Savaysa.

DelveInsight Atrial Fibrillation-Market Insights & Drugs Sales Forecast (AF) -2020 provides an overview of Atrial Fibrillation indication. The Report majorly emphasize on the global Anticoagulants market size and market size of the Anticoagulants by 7Major Markets (United States, EU5 (France, Germany, Italy, Spain, UK) and Japan). The Report also covers the market size of Atrial Fibrillation along with the market sales of the Key drugs by AF.  The Report provides comprehensive review of Market Drivers, Market barriers, Anticoagulants with coverage of detailed profile, Cost of therapy, Safety and Efficacy profiles and SWOT analysis.

With the new guideline by regulatory agencies has promoted the use of NOACs over warfarin. Atrial Fibrillation guidelines has also encouraged to use CHA2DS2-VASc score instead of the CHADS2 score for assessing stroke risk, which will cause a larger proportion of lower risk patients to receive anticoagulant treatment.

For more information email us @ info@delveinsight.com.

Downloads

Article in PDF

Recent Articles
  1. Business cocktail
  2. Sun Pharma & ICGEB announce collaboration; Boehringer Ingelheim and Lupin Sign deal; Daiichi...
  3. DelveInsight- Business Consultant and Knowledge Partner
  4. Roche’s Phase 2 data; Celgene and Bluebird’s CAR-T therapy; Regeneron/Sanofi gets results; Allerg...
  5. Notizia
pharma-news-for-applied-therapeutics-alnylam-rigel
Notizia - Recent Pharma, Healthcare and Biotech Happenings

FDA Grants Fast Track for Lin BioScience’s LBS-007; Alnylam’s AMVUTTRA sNDA Under Review; FDA Approves RAPIBLYK for Atrial Fibrillation; Applied Therapeutics Receives CRL for Govorestat in Galactosemia; R289 Gets Fast Track for Lower-Risk MDS.

pharma-news-for-regeneron-astrazeneca-syndax
Notizia - Recent Pharma, Healthcare and Biotech Happenings

FDA Approves PTC’s AADC Gene Therapy; DUPIXENT sBLA Acceptance for Urticaria; CHMP Recommends TAGRISSO for EGFR Lung Cancer; FDA Approves DANZITEN for CML; Syndax Wins FDA Approval for REVUFORJ in Acute Leukemia

Pharma-news-for-autolus-unicycive-abbvie
Notizia - Recent Pharma, Healthcare and Biotech Happenings

AUCATZYL Approved for R/R B-ALL; FDA Accepts NDA for Unicycive’s Oxylanthanum Carbonate; AstraZeneca and Amgen Report Positive Results in Chronic Rhinosinusitis; Nipocalimab Granted Breakthrough Designation for Sjögren’s Disease; AbbVie’s Schizophrenia Drug Fails Phase Studies

Business Consultant
Cardiovascular disease
collaborations
Competitive landscape
DelveInsight
Discovery
Drug
Hematological disorders
licensing opportunities
Market Forecasting
Market Research
market trends
Metabolic disorders
Phase III Pipeline
Pipeline
Pipeline coverage
Reports
SWOT ANALYSIS
technology assessments
Track your closest Competitors
loader